Published in final edited form as:

Angew Chem Int Ed Engl. 2011 September 19; 50(39): 9112–9115. doi:10.1002/anie.201102790.

Enantioselective Synthesis of (–)-Exiguolide by Iterative Stereoselective Dioxinone-Directed Prins Cyclizations

Erika A. Crane, Thomas P. Zabawa[Dr.], Rebecca L. Farmer, and Karl A. Scheidt* [Prof. Dr.]

Department of Chemistry Center for Molecular Innovation and Drug Discovery Chemistry of Life Processes Institute Silverman Hall, Northwestern University Evanston, IL 60208 (USA)

Keywords

antitumor agents; biological activity; dioxinones; Prins cyclization; total synthesis

Exiguolide (**1**, Scheme 1) is an unusual natural product isolated in 2006 by Ohta, Ikegami, and co-workers from the marine sponge *Geodia exigua* Thiele.^[1] This molecule inhibits the fertilization of sea urchin gametes (*H. pulcherrimus*) at a concentration of 20 μM but does not affect the development of the already fertilized eggs at higher concentrations (100 μM), thus indicating that it might possess relevant anticancer activity.^[2] The similarity of compound **1** to the bryostatin family of natural products, which are known antitumor compounds, was proposed by Cossy^[3] and also intrigued us. In particular, the bispyran architecture and the exocyclic enoate appended onto a tetrahydropyran ring are motifs common to both exiguolide and the bryostatins.^[4]

The first synthesis of exiguolide was reported by Lee and co-workers, who established the absolute configuration of the natural product.^[5a] The current synthetic approaches to this 16-membered macrolide tend to rely on linear macrolactonization strategies by esterification to establish the primary ring system.^[5] While these polyketide/macrolide strategies are effective, we sought a complimentary approach by focusing on maximum convergency and flexibility for biological studies. Indeed, this target seemed ideal to deploy a unified strategy to construct the tetrahydropyran (THP) rings and the macrocycle in an efficient manner.^[6] Given the inherent challenges involving macrocyclizations in many total synthesis campaigns with only slight modifications of related substrates,^[7] this target also offered the opportunity to expand our Prins-type cyclization strategy^[8] to larger ring sizes beyond those previously examined by us.^[6c] Herein, we report the enantioselective synthesis of (–)-exiguolide by employing iterative and stereoselective dioxinone-based Prins reactions.

Our synthetic plan, detailed in Scheme 1, involved 1) a late-stage Cu^{I} -mediated cross-coupling to construct the triene side chain, 2) an olefination with an enantiomerically enriched Horner–Wadsworth–Emmons (HWE) reagent to install the exocyclic unsaturated ester, and 3) an intramolecular dioxinone Prins cyclization to simultaneously build the 16-membered macrocycle and generate one of the two THP rings. The linear precursor (**2**) would be assembled by an intermolecular Prins cyclization of a dioxinone (**4b**) and an aldehyde (**5**) to create the 2,6-*cis*-tetrahydropyran ring. An esterification to append a second dioxinone fragment (a carboxylic acid derived from **4a**) would install the entire carbon framework without the triene side chain and the exocyclic enoate. Notably, a key β -hydroxy

dioxinone fragment would be employed twice to construct aldehyde **2**, thereby streamlining the synthesis and improving the overall efficiency.

Our synthesis commenced with a catalytic, asymmetric acyl halide/aldehyde cyclocondensation developed by Nelson et al.^[9] of alkyne **6** and propionyl bromide **7** in the presence of Al^{III} catalyst **I** to provide the cis-substituted β lactone **8** (Scheme 2). The lactone was converted to the Weinreb amide **9** (72% yield over two steps), which facilitated the assessment of the diastereoselectivity (d.r. > 20:1) and enantioselectivity (90% *ee*) of the cyclocondensation process. The resulting alcohol **9** was protected as the TBS ether, and an allyl Grignard addition followed by an olefin isomerization, which was catalyzed by Hünig's base, afforded α,β -unsaturated ketone **10**. A subsequent asymmetric reduction to the allylic alcohol was performed using Corey–Bakshi–Shibata conditions^[10] and followed by heating with *N,N*-dimethylacetamide dimethyl acetal in order to promote an Eschenmoser–Claisen rearrangement^[11] to deliver amide **11** in 85% yield. This sequence efficiently and selectively installed the *E* olefin with the necessary geometry and established the stereocenter that bears the methyl group. The transformation to aldehyde **5** occurred by reduction of amide **11** with LiNH₂BH₃ to the primary alcohol,^[12] subsequent oxidation with Dess–Martin periodinane to the aldehyde,^[13] and removal of the TBS protecting group under acidic conditions (77% yield over three steps).

The related dioxinone fragments **4a** and **4b** were accessed using a catalytic enantioselective vinylogous aldol reaction reported by Scettri and co-workers (Scheme 3).^[6c,14] Protecting-group manipulations and oxidation of dioxinone **4a** afforded acid **13** in 73% yield over three steps. The requisite vinyl iodide fragment **3** was constructed by a Wittig olefination of aldehyde **14**^[15] by using the Stork–Zhao protocol.^[16] To obtain the desired *E/Z* selectivity of the diene, it was essential to use DMF as solvent with HMPA, and to maintain the reaction temperature at –78°C.^[17] The removal of the TBS group from the vinyl iodide product afforded alcohol **15**, which underwent sequential Dess–Martin and Pinnick^[18] oxidations and treatment with diazomethane to afford coupling partner **3** (50% over three steps).

With the appropriate fragments constructed, we explored the first Prins cyclization for the union of aldehyde **5** and dioxinone **4b** (Scheme 4). Following an extensive survey of reaction conditions and protecting groups (not shown), we found that the desired cyclization proceeded only when we used more robust Lewis acids, such as BF₃·OEt₂; however, we observed variable loss of protecting groups under these conditions. The most reproducible and highest yielding reactions utilized BF₃·OEt₂ as the Lewis acid and calcium sulfate as the drying agent. Overall, this intermolecular dioxinone Prins coupling produced the desired pyranone ring in 55% yield on a gram scale (combined yields of **16** and **17**).

At this point, protecting-group manipulation of both **16** and **17** produced bicyclic dioxinone **18** (Scheme 5).^[19] Subsequent decarboxylation of cyclization product **18** by heating in xylenes led to the cyclohexanone product. Removal of the carbonyl group from the THP ring was then achieved efficiently by reduction with sodium borohydride to form the pyranol, iodination, and radical-mediated dehalogenation to afford pyran **19**. The acetate protecting group of **19** was removed and the resulting secondary alcohol was esterified with dioxinone acid **13**.^[20] A global deprotection and the selective oxidation of the primary alcohol to the aldehyde was achieved with a silica gel accelerated catalytic oxidation using TEMPO and PhI(OAc)₂.^[21]

The key macrocyclization of linear precursor **2** proceeded smoothly, forming both the THP ring and the macrocycle concurrently. In contrast to the earlier intermolecular Prins reaction, catalytic conditions using scandium(III) (50 mol% of Sc(OTf)₃) effectively promoted the

cyclization of the 16-membered macrocycle and the second pyran ring in 66% yield. The decarboxylation of bicyclic dioxinone **20**, a Horner–Wadsworth–Emmons olefination with a phosphonate derived from (*S*)-1,1'-bi-2-naphthol (**II**),^[22] and deprotection of the TMS group afforded terminal alkyne **21** with an enoate isomer ratio of *Z/E* = 7:1. The completion of the synthesis necessitated appending the polyene side chain with control of the sensitive *E/Z/E* triene. After significant development, a selective hydrostannylation proceeded smoothly to afford predominantly the *E*-vinyl stannane.^[23] While a Pd⁰-catalyzed Stille coupling afforded complex mixtures of products, a Liebeskind Cu^I-mediated coupling^[24] afforded (–)-exiguolide, which gratifyingly possessed identical physical data to the natural material.^[25]

Subsequently, we evaluated the ability of exiguolide to inhibit cancer cell growth. We suspected that exiguolide would possess antiproliferative activity because of its structural similarities to the bryostatin natural products, as well as its activity against sea urchin gamete formation. To test this hypothesis, a variety of late-stage intermediates, including exiguolide (**1**), 28-(*E*)-exiguolide (**22**), alkene **23**, and alkyne **21** were screened against nine cancer cell lines in an MTS assay (Figure 1). From all of the cell lines examined,^[26] exiguolide demonstrated significant antiproliferative activity against A549 lung cancer cells, inhibiting their growth by (52±6)% at 10 μM and (26±6)% at 1 μM. Additionally, the natural product also showed moderate growth inhibition against other cell lines, inhibiting growth of PC3 prostate cancer cells ((35±7)%), MDA-MB-231 breast cancer cells ((30±10)%), and BxPC3 pancreatic cancer cells ((33±9)%) at 10 μM. The intriguing observation that exiguolide specifically inhibits A549 lung cancer cell growth with a higher potency than it exhibits against the other cell lines tested was first reported by Fuwa et al.^[27] and subsequently confirmed by us. This fact underscores that this natural product or related congeners have potential as selective biological tools for oncology research and as chemotherapeutic agents. Interestingly, 28-(*E*)-exiguolide (**22**), macrocyclic alkene **23**, and macrocyclic alkyne **21** all demonstrated only minimal activity against all of the cell lines, thus indicating that the triene side chain and the *Z*-enoate geometry are both essential for the biological activity. The fact that only the *Z*-enoate is active in our assays is particularly relevant, as this finding closely mirrors the results of structure–activity–relationship studies on the bryostatin family of natural products,^[4b] and presents new structure–activity–relationship (SAR) data when compared to the recent report by Fuwa et al.^[27] Further studies to enhance and understand this selective activity are underway.

In summary, we have completed a convergent synthesis of (–)-exiguolide in 26 steps (longest linear route) by employing a unified Prins cyclization approach. This strategy employs two highly diastereoselective dioxinone-directed Prins reactions, which are integral in constructing both tetrahydropyran rings of the molecule: the first to unify the highly functionalized substrates in the construction of the linear precursor of exiguolide, and the second in a 16-membered macrocyclization, which simultaneously installs the second THP ring. The route described herein is highly modular and combines two similar dioxinone fragments and one aldehyde component to generate the core structure of the target. Preliminary biological screening suggests that this natural product selectively inhibits the growth of a number of cancer cell lines, and that the triene side chain and *Z*-enoate geometry are required for the observed growth inhibition. This flexible strategy, which is driven by the Prins reaction, enables the coupling and cyclization of complex substrates and should be applicable to related targets to continue our chemical-biological investigations.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support for this work was provided by the NCI (RO1 CA126827 and SPORE in Prostate Cancer P50 CA090386), the American Cancer Society (Research Scholar Award to K.A.S.) and Amgen. We are grateful to Boehringer-Ingelheim for the New Investigator Award in Organic Chemistry supporting T.P.Z. R.L.F. thanks the NIH for a predoctoral fellowship (F31CA138097). E.A.C. and R.L.F. thank the Malkin Scholars Program for additional support (Robert H. Lurie Comprehensive Cancer Center at Northwestern University). We would like to thank Dr. Andrew Mazar, Keith Macrenaris, Rich Ahn, and Elden Swindell (NU) for providing the cancer cell lines and cell culture technical support.

References

- [1]. Ohta S, Uy MM, Yanai M, Ohta E, Hirata T, Ikegami S. *Tetrahedron Lett.* 2006; 47:1957–1960.
- [2]. The sea urchin is a model organism for evolutionary biology, embryology, and gene regulation, see: a) Ransick A, Rast JP, Minokawa T, Calestani C, Davidson EH. *Dev. Biol.* 2002; 246:132–147. [PubMed: 12027439] ; b) Wang X, Feng T, Yang L, Liu C, Meng X, Qiu X. *Conserv. Genet.* 2009; 10:729–731..
- [3]. Cossy J. C. R. *Chim.* 2008; 11:1477–1482.
- [4]. a) Szallasi Z, Smith CB, Pettit GR, Blumberg PM. *J. Biol. Chem.* 1994; 269:2118–2124. [PubMed: 8294465] b) Wender PA, DeChristopher BA, Schrier AJ. *J. Am. Chem. Soc.* 2008; 130:6658–6659. [PubMed: 18452292]
- [5]. For total syntheses, see: a) Kwon MS, Woo SK, Na SW, Lee E. *Angew. Chem.* 2008; 120:1757–1759. *Angew. Chem. Int. Ed.* 2008, 47, 1733 - 1735. ; b) Fuwa H, Sasaki M. *Org. Lett.* 2010; 12:584–587. [PubMed: 20063897] ; c) Cook C, Guinchard X, Liron F, Roulland E. *Org. Lett.* 2010; 12:744–747. [PubMed: 20078080] . For synthetic studies on exiguolide, see: C. R. Reddy, N. N. Rao, *Tetrahedron Lett.* 2010, 51, 5840 - 5842.
- [6]. a) Morris WJ, Custar DW, Scheidt KA. *Org. Lett.* 2005; 7:1113–1116. [PubMed: 15760152] b) Biddle MM, Lin M, Scheidt KA. *J. Am. Chem. Soc.* 2007; 129:3830–3831. [PubMed: 17348659] c) Custar DW, Zabawa TP, Scheidt KA. *J. Am. Chem. Soc.* 2008; 130:804–805. [PubMed: 18161979] d) Custar DW, Zabawa TP, Hines J, Crews CM, Scheidt KA. *J. Am. Chem. Soc.* 2009; 131:12406–12414. [PubMed: 19663512] e) Farmer RL, Biddle MM, Nibbs AM, Huang X, Li X, Bergan RC, Scheidt KA. *ACS Med. Chem. Lett.* 2010; 1:400–405. [PubMed: 21116437] f) Tenenbaum JM, Morris WJ, Custar DW, Scheidt KA. *Angew. Chem.* 2011; 123:6014–6017. *Angew. Chem. Int. Ed.* 2011, 50, 5892 - 5895.
- [7]. For recent selected examples of challenging macrocyclizations in total synthesis, see: a) Ghidu VP, Wang J, Wu B, Liu Q, Jacobs A, Marnett LJ, Sulikowski GA. *J. Org. Chem.* 2008; 73:4949–4955. [PubMed: 18543990] ; b) Wender PA, Loy BA, Scheier AJ. *Isr. J. Chem.* 2011; 51:453–472.. For recent selective examples of highly substrate dependant macrocyclization, see: c) Hanson PR, Chengondi R, Nyugen J, Thomas CD, Waetzig JD, Whitehead A. *J. Org. Chem.* 2011; 76:4358–4370. [PubMed: 21528846] .
- [8]. For recent Prins-type macrocyclizations, see: a) Woo SK, Kwon MS, Lee E. *Angew. Chem.* 2008; 120:3286–3288. *Angew. Chem. Int. Ed.* 2008, 47, 3242 - 3244. ; b) Bahnck KB, Rychnovsky SD. *J. Am. Chem. Soc.* 2008; 130:13177–13181. [PubMed: 18767844] ; c) Woo SK, Lee E. *J. Am. Chem. Soc.* 2010; 132:4564–4565. [PubMed: 20222708] ; d) Gesinski MR, Tadpetch K, Rychnovsky SD. *Org. Lett.* 2009; 11:5342–5345. [PubMed: 19873984] ; e) Yadav JS, Kumar GGKSN. *Tetrahedron.* 2010; 66:480–487.. For a review, see: E. A. Crane, K. A. Scheidt, *Angew. Chem.* 2010, 122, 8494 - 8505; *Angew. Chem. Int. Ed.* 2010, 49, 8316 - 8326.
- [9]. a) Nelson SG, Peelen TJ, Wan Z. *J. Am. Chem. Soc.* 1999; 121:9742–9743. b) Nelson SG, Wan ZH. *Org. Lett.* 2000; 2:1883–1886. [PubMed: 10891182]
- [10]. An Evans–Tishchenko reduction failed with deprotected 10. Other reductions that did not produce the desired selectivity include the use of sodium borohydride, zinc borohydride, as well as l-Selectride and BINAL.
- [11]. a) Wick AE, Felix D, Steen K, Eschenmoser A. *Helv. Chim. Acta.* 1964; 47:2425–2427. b) Mulzer J, Bats JW, List B, Opatz T, Trauner D. *Synlett.* 1997:441–444.
- [12]. Myers AG, Yang BH, David KJ. *Tetrahedron Lett.* 1996; 37:3623–3626.
- [13]. Dess DB, Martin JC. *J. Am. Chem. Soc.* 1991; 113:7277–7287.

- [14]. De Rosa M, Acocelli MR, Villano R, Soriente A, Scettri A. *Tetrahedron: Asymmetry*. 2003; 14:2499–2502.
- [15]. a) Alvarez R, Herrero M, Lopez S, de Lera AR. *Tetrahedron*. 1998; 54:6793–6810. b) McLaughlin MJ, Hsung RP. *J. Org. Chem.* 2001; 66:1049–1053. [PubMed: 11430073]
- [16]. Stork G, Zhao K. *Tetrahedron Lett.* 1989; 30:2173–2174.
- [17]. a) Bergelson LD, Barsukov LI, Shemyakin MM. *Tetrahedron*. 1967; 23:2709–2720. b) Maryanoff BE, Reitz AB, Mutter MS, Inners RR, Almond HR, Whittle RR, Olofson RA. *J. Am. Chem. Soc.* 1986; 108:7664–7678. [PubMed: 22283272]
- [18]. Bal BS, Childers WE, Pinnick HW. *Tetrahedron*. 1981; 37:2091–2096.
- [19]. a) Selective TBDPS protection conditions: TBDPSCl, DMAP, pyridine, CH₂Cl₂, 0 to 23°C, 80% yield (17 to 16); b) Acetate protecting conditions: Ac₂O, pyridine, DMAP, CH₂Cl₂, 83% yield (16 to 18).
- [20]. Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. *Chem. Bull.* 1979; 52:1989–1993.
- [21]. For acid-promoted oxidations of alcohols with TEMPO, see: Ma Z, Bobbitt JM. *J. Org. Chem.* 1991; 56:6110–6114.
- [22]. a) Tanaka K, Ohta Y, Fuji K, Taga T. *Tetrahedron Lett.* 1993; 34:4071–4074. b) Tanaka K, Otsubo K, Fuji K. *Tetrahedron Lett.* 1996; 37:3735–3738. c) Evans DA, Carter PH, Carreira EM, Charette AB, Prunet JA, Lautens M. *J. Am. Chem. Soc.* 1999; 121:7540–7552. d) Ohmori K, Ogawa Y, Obitsu T, Ishikawa Y, Nishiyama S, Yamamura S. *Angew. Chem.* 2000; 112:2376–2379. *Angew. Chem. Int. Ed.* 2000, 39, 2290 - 2294. e) Kageyama M, Tamura T, Nantz MH, Roberts JC, Somfai P, Whritenour DC, Masamune S. *J. Am. Chem. Soc.* 1990; 112:7407–7408. f) Maguire RJ, Munt SP, Thomas EJ. *J. Chem. Soc. Perkin Trans. 1*. 1998:2853–2863. g) Lampe TFJ, Hoffmann HMR. *Tetrahedron Lett.* 1996; 37:7695–7698. h) Hale KJ, Hummerson MG, Bhatia GS. *Org. Lett.* 2000; 2:2189–2192. [PubMed: 10930240] i) Trost BM, Yang HB, Thiel OR, Frontier AJ, Brindle CS. *J. Am. Chem. Soc.* 2007; 129:2206–2207. [PubMed: 17279751]
- [23]. a) Trost BM, Ball ZT. *Synthesis*. 2005; 6:853–887. b) Netherton MR, Fu GC. *Org. Lett.* 2001; 3:4295–4298. [PubMed: 11784201] c) Darwish A, Lang A, Kim T, Chong JM. *Org. Lett.* 2008; 10:861–864. [PubMed: 18237179]
- [24]. Allred GD, Liebeskind LS. *J. Am. Chem. Soc.* 1996; 118:2748–2749.
- [25]. Synthetically derived compound **1** possessed identical characterization data (¹H NMR, ¹³C NMR, HRMS, IR) to the values reported for the natural material. Optical rotation for synthetic material: [α]_D²⁰ = –81.4 (CHCl₃, c = 0.07), optical rotation for the isolated material: [α]_D²⁵ = –92.5 (CHCl₃, c = 0.069). See the Supporting Information for details.
- [26]. Tested cell lines: A549 (lung), HT-29 (colorectal), RT4 (urinary bladder), HT1080 (fibrosarcoma), FaDu (pharynx), MDA-MB-231 (breast), OVCAR-3 (ovarian), BxPC-3 (pancreatic), and PC-3 (prostate). See the Supporting Information for details.
- [27]. During the preparation of this manuscript, the antiproliferative activity of (–)-**1** against various tumor cells was reported: Fuwa H, Suzuki T, Kubo H, Yamori T, Sasaki M. *Chem. Eur. J.* 2011; 17:2678–2688. [PubMed: 21264972].

Figure 1.
Exiguolide and analogues that were evaluated against tumor cell lines.

Scheme 1.
Retrosynthetic strategy.

Scheme 2.

Aldehyde fragment synthesis. a) $i\text{Pr}_2\text{NEt}$, 10 mol% **I**, CH_2Cl_2 , -50°C ; b) $\text{MeONHMe}\cdot\text{HCl}$, $i\text{Pr}_2\text{NEt}$, CH_2Cl_2 , 72% over 2 steps; c) TBSCl , imidazole , CH_2Cl_2 , 89% yield; d) allylMgBr , diethyl ether, 0°C ; e) $i\text{Pr}_2\text{NEt}$, 94% over 2 steps; f) $(S)\text{-CBS}$ catalyst (**12**), $\text{BH}_3\cdot\text{OME}_2$, THF , -15°C , 70% yield; g) $\text{MeC(OMe)}_2\text{NMe}_2$, xylenes, 140°C , 85% yield; h) LiNH_2BH_3 , THF , 0°C , 93% yield; i) DMP , NaHCO_3 , CH_2Cl_2 , 99% yield; j) HCl (aq), THF , 84% yield. Bn= benzyl, DMP= Dess–Martin periodinane, $(S)\text{-CBS}$ = $(S)\text{-}(-)\text{-}2\text{-methyl-CBS-oxazaborolidine}$, TBS= *tert*-butyldimethylsilyl, TMS= trimethylsilyl.

Scheme 3.

Dioxinone and vinyl iodide syntheses. a) TBSCl, imidazole, DMF, 91% yield; b) PPTS, EtOH, 83% yield; c) PDC, DMF, 97% yield; d) $\text{PPh}_3\text{CH}_2\text{I}_2$, NaHMDS, HMPA, DMF, -78°C ; e) PPTS, MeOH, 61% yield over two steps; f) DMP, CH_2Cl_2 ; g) NaClO_2 , NaH_2PO_4 , 2-Me-2-butene, *t*BuOH, H_2O ; h) TMSCHN_2 , MeOH, benzene, 50% yield over 3 steps. DMF=*N,N*-dimethylformamide, HMDS=hexamethyldisilazide, HMPA=hexamethylphosphoramide, PDC=pyridinium dichromate, PG=protecting group, PPTS=pyridinium *p*-toluenesulfonate, TBDPS=*tert*-butyldiphenylsilyl.

Scheme 4.
Fragment-assembly Prins cyclization.

Scheme 5.

Macrocyclization and completion of the synthesis. a) Xylenes, H₂O, 130°C, 81% yield; b) NaBH₄, MeOH, -10°C, 76% yield; c) NIS, PPh₃, imidazole, CH₂Cl₂, 82% yield; d) Bu₃SnH, AIBN, toluene, 80°C, 91% yield; e) DIBAL-H, hexanes, -78°C, 76% yield; f) acid **13**, C₆Cl₃H₂COCl, NEt₃, DMAP, THF, 91% yield; g) HF·pyridine, THF, 85% yield; h) TEMPO, SiO₂, C₆H₅I(OAc)₂, CH₂Cl₂, 86% yield; i) 50 mol% Sc(OTf)₃, CaSO₄, MeCN, 0°C, 66% yield; j) DMSO, H₂O, 130°C, 85% yield; k) phosphonate **II**, NaHMDS, THF, -78°C → -40°C, 62% yield; l) *n*Bu₄NF, THF, 0°C 80% yield; m) 0.5 mol% [Pd₂(dba)₃], 2 mol% Cy₃PHBF₄, 20 mol% *i*Pr₂NEt, HSnBu₃, toluene, -78°C, 72% yield; n) vinyl iodide **3**, CuTC **III**, NMP, 0°C, 75% yield. AIBN=azobisisobutyronitrile, Cy=cyclohexyl, dba=*trans,trans*-dibenzylidenacetone, DIBAL-H=diisobutylaluminium hydride, DMAP= 4-dimethylaminopyridine, DMSO=dimethyl sulfoxide, NIS=*N*-iodosuccinimide, NMP=*N*-methylpyrrolidinone, TC=thiophene carboxylate, TEMPO= (tetramethylpiperidinyloxy), Tf=trifluoromethanesulfonyl.